Original Research

DOI: 10.4244/EIJ-D-24-00240

Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial

Sripal Bangalore1, MD, MHA; Grace Rhodes2, MS; David J. Maron3, MD; Rebecca Anthopolos1, DrPH; Sean M. O’Brien2, PhD; Philip G. Jones4, MS; Daniel B. Mark2, MD; Harmony R. Reynolds1, MD; John A. Spertus4, MD, MPH; Gregg W. Stone5, MD; Harvey D. White6, DSc; Yifan Xu1, MPH; Stephen E. Fremes7, MD; Judith S. Hochman1, MD; on behalf of the ISCHEMIA Research Group

Abstract

BACKGROUND: Whether revascularisation (REV) improves outcomes in patients with three-vessel coronary artery disease (3V-CAD) is uncertain.

AIMS: Our objective was to evaluate outcomes with REV (percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery [CABG]) versus medical therapy in patients with 3V-CAD.

METHODS: ISCHEMIA participants with 3V-CAD on coronary computed tomography angiography without prior CABG were included. Outcomes following initial invasive management (INV) with REV (PCI or CABG) versus initial conservative management (CON) with medical therapy alone were evaluated. Regression modelling was used to estimate the outcomes if all participants were to undergo prompt REV versus those assigned to CON. Outcomes were cardiovascular (CV) death/myocardial infarction (MI), death, CV death, and quality of life. Bayesian posterior probability for benefit (Pr [benefit]) for 1 percentage point lower 4-year rates with REV versus CON were evaluated.

RESULTS: Among 1,236 participants with 3V-CAD (612 INV/624 CON), REV was associated with lower 4-year CV death/MI (adjusted 4-year difference: −4.4, 95% credible interval [CrI] −8.7 to −0.3 percentage points, Pr [benefit]=94.8%) when compared with CON, with similar results for PCI versus CON (−5.8, 95% CrI: −10.8 to −0.5 percentage points, Pr [benefit]=96.4%) and CABG versus CON (−3.7, 95% CrI: −8.8 to 1.5 percentage points, Pr [benefit]=84.7%). Adjusted 4-year REV versus CON differences were as follows: death −1.2 (95% CrI: −4.7 to 2.2) percentage points, CV death −2.3 (95% CrI: −5.5 to 0.8) percentage points, with similar results for PCI and for CABG. The Pr (benefit) for death with REV (PCI or CABG) versus CON was 49-63%. The adjusted 12-month Seattle Angina Questionnaire-7 summary score differences favoured REV: REV versus CON 4.6 (95% CrI: 2.7-6.4) percentage points; PCI versus CON 3.6 (95% CrI: 1.2-5.8) percentage points and CABG versus CON 4.3 (95% CrI: 1.5-6.9) percentage points with high Pr (benefit).

CONCLUSIONS: In participants with 3V-CAD, REV (either PCI or CABG) was associated with a lower 4-year CV death/MI rate and improved quality of life, with similar results for PCI versus CON and CABG versus CON. The differences in all-cause mortality between REV and CON were small with wide confidence intervals. (ClinicalTrials.gov: NCT01471522)

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 20
Oct 21, 2024
Volume 20 Number 20
View full issue


Key metrics

Suggested by Cory

Editorial

10.4244/EIJ-E-24-00046 Oct 21, 2024
Phoenix rising: a credible signal for CABG from ISCHEMIA?
Bittl J
free

Mar 21, 2011
Risk-benefit trade-offs in revascularisation choices
Federspiel J et al
free

10.4244/EIJV16I12A174 Dec 18, 2020
Translating the findings of ISCHEMIA into clinical practice: a challenging START
Boden W and Bhatt D
free
Trending articles
225.68

State-of-the-Art Review

10.4244/EIJ-D-21-00426 Dec 3, 2021
Myocardial infarction with non-obstructive coronary artery disease
Lindahl B et al
free
105.78

Expert consensus

10.4244/EIJ-E-22-00018 Dec 4, 2023
Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations
Lunardi M et al
free
77.85

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
68.7

Clinical research

10.4244/EIJ-D-21-00545 Sep 20, 2022
Coronary lithotripsy for the treatment of underexpanded stents: the international; multicentre CRUNCH registry
Tovar Forero M et al
free
47.8

NEW INNOVATION

10.4244/EIJ-D-15-00467 Feb 20, 2018
Design and principle of operation of the HeartMate PHP (percutaneous heart pump)
Van Mieghem NM et al
free
45.3

Clinical research

10.4244/EIJ-D-18-01126 Aug 29, 2019
New-generation mechanical circulatory support during high-risk PCI: a cross-sectional analysis
Ameloot K et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved